Wilson Sonsini Represents Novo Holdings on BIOMILQ, Inc.’s $21 Million Series A Financing

On October, 20, 2021, North Carolina-based mammary biotechnology company BIOMILQ, Inc., announced the successful close of $21 million in Series A financing, which will enable their acceleration of bringing cell-cultured human milk to market. Leading the fundraise are Danish life science investor Novo Holdings and clean tech leader Breakthrough Energy Ventures. Additional support comes from Blue Horizon, Spero Ventures, Digitalis Ventures, Green Generation Fund, Alexandria and Gaingels. Wilson Sonsini Goodrich & Rosati represented Novo Holdings on the transaction.

Investment partners for the round were selected based in part on alignment with BIOMILQ’s core set of values: having female leadership within their fund, having a portfolio of diverse founders, and having an internal mandate for positive impact in the world. Utilizing proprietary technology, BIOMILQ announced capability for producing human milk outside of the body this year. The additional funds from the fundraise will accelerate their process development and optimization, enabling full commercialization over the next 4 years.

The Wilson Sonsini team that represented Novo Holdings on the transaction includes:

Corporate:
Dan Koeppen
Kassandra Castillo
Bridget Balisy

Intellectual Property:
Mike Hostetler
Deborah Smith

National Security:
Stephen Heifetz
Jonathan Davey

For more information, please see BIOMILQ’s press release